PetVivo Engages Another Top Sales Manager, Cindy Gill, for Regional Business Development Manager, as Adoption of Breakthrough Animal MedTech Device Continues to Spread Nationwide
PetVivo Holdings, Inc. (OTCQB: PETV, PETVW) has appointed Cindy Gill as field veterinary business development manager for Oklahoma, Arkansas, and northern Texas. Gill brings significant veterinary industry experience, having worked for companies like Lintbells, Midwest Veterinary Supply, and Merck. She will focus on expanding sales of PetVivo's flagship product, Spryng™ with OsteoCushion™ Technology, a revolutionary injectable medical device for managing osteoarthritis in animals.
Spryng has shown effectiveness in improving medical outcomes for animals with lameness and joint-related afflictions. It has been used by over 800 veterinary clinics across 50 states, with more than 10,000 syringes distributed nationwide. This success reflects the growing U.S. animal health market, projected to reach $11.3 billion by 2030.
PetVivo Holdings, Inc. (OTCQB: PETV, PETVW) ha nominato Cindy Gill come manager dello sviluppo commerciale per veterinari sul campo per l'Oklahoma, l'Arkansas e il Texas settentrionale. Gill porta con sé una significativa esperienza nel settore veterinario, avendo lavorato per aziende come Lintbells, Midwest Veterinary Supply e Merck. Si concentrerà sull'espansione delle vendite del prodotto di punta di PetVivo, Spryng™ con Tecnologia OsteoCushion™, un dispositivo medico iniettabile rivoluzionario per la gestione dell'osteoartrite negli animali.
Spryng ha dimostrato efficacia nel migliorare i risultati medici per gli animali con zoppia e afflizioni articolari. È stato utilizzato in oltre 800 cliniche veterinarie in tutti gli Stati Uniti, con più di 10.000 siringhe distribuite a livello nazionale. Questo successo riflette la crescita del mercato della salute animale negli Stati Uniti, che si prevede raggiungerà i 11,3 miliardi di dollari entro il 2030.
PetVivo Holdings, Inc. (OTCQB: PETV, PETVW) ha nombrado a Cindy Gill como gerente de desarrollo comercial veterinario de campo para Oklahoma, Arkansas y el norte de Texas. Gill aporta una experiencia significativa en la industria veterinaria, habiendo trabajado para empresas como Lintbells, Midwest Veterinary Supply y Merck. Se enfocará en expandir las ventas del producto insignia de PetVivo, Spryng™ con Tecnología OsteoCushion™, un dispositivo médico inyectable revolucionario para el manejo de la osteoartritis en animales.
Spryng ha demostrado ser efectivo en la mejora de los resultados médicos para los animales con cojera y afecciones articulares. Ha sido utilizado por más de 800 clínicas veterinarias en 50 estados, con más de 10,000 jeringas distribuidas a nivel nacional. Este éxito refleja el creciente mercado de salud animal en EE. UU., que se proyecta alcanzará los 11.3 mil millones de dólares para 2030.
PetVivo Holdings, Inc. (OTCQB: PETV, PETVW)는 Cindy Gill을 오클라호마, 아칸소, 북부 텍사스의 현장 수의학 비즈니스 개발 매니저로 임명했습니다. Gill은 Lintbells, Midwest Veterinary Supply 및 Merck와 같은 회사에서 근무하며 상당한 수의학 산업 경험을 쌓았습니다. 그녀는 PetVivo의 주력 제품인 Spryng™와 OsteoCushion™ 기술의 판매 확대에 집중할 것입니다. 이 혁신적인 주사형 의료 장치는 동물의 골관절염 관리에 사용됩니다.
Spryng은 절뚝거림 및 관절 관련 질병을 앓고 있는 동물의 치료 결과 개선에 효과적임을 보여주었습니다. 현재 50개 주의 800개 이상의 수의학 클리닉에서 사용되고 있으며, 10,000개 이상의 주사기가 전국적으로 배포되었습니다. 이 성공은 2030년까지 113억 달러에 이를 것으로 예상되는 미국의 동물 건강 시장의 성장 반영합니다.
PetVivo Holdings, Inc. (OTCQB: PETV, PETVW) a nommé Cindy Gill en tant que responsable du développement commercial vétérinaire sur le terrain pour l'Oklahoma, l'Arkansas et le Texas nord. Gill possède une expérience significative dans l'industrie vétérinaire, ayant travaillé pour des entreprises telles que Lintbells, Midwest Veterinary Supply et Merck. Elle se concentrera sur l'expansion des ventes du produit phare de PetVivo, Spryng™ avec Technologie OsteoCushion™, un dispositif médical injectable révolutionnaire pour la gestion de l'arthrose chez les animaux.
Spryng a montré son efficacité dans l'amélioration des résultats médicaux pour les animaux ayant des boiteries et des affections articulaires. Il a été utilisé par plus de 800 cliniques vétérinaires à travers 50 États, avec plus de 10 000 seringues distribuées à l'échelle nationale. Ce succès reflète la croissance du marché de la santé animale aux États-Unis, qui, selon les prévisions, atteindra 11,3 milliards de dollars d'ici 2030.
PetVivo Holdings, Inc. (OTCQB: PETV, PETVW) hat Cindy Gill zur Managerin für die Geschäftsentwicklung im veterinärmedizinischen Außendienst für Oklahoma, Arkansas und Nordtexas ernannt. Gill bringt umfangreiche Erfahrung in der Tiermedizinbranche mit, da sie für Unternehmen wie Lintbells, Midwest Veterinary Supply und Merck gearbeitet hat. Sie wird sich auf die Erweiterung der Verkaufszahlen von PetVivos Flaggschiffprodukt Spryng™ mit OsteoCushion™-Technologie konzentrieren, einem revolutionären injizierbaren Medizinprodukt zur Behandlung von Osteoarthritis bei Tieren.
Spryng hat sich als wirksam erwiesen, wenn es darum geht, die medizinischen Ergebnisse bei Tieren mit Lahmheit und gelenkbezogenen Beschwerden zu verbessern. Es wurde in über 800 tierärztlichen Kliniken in 50 Bundesstaaten eingesetzt, mit mehr als 10.000 verteilten Spritzen im ganzen Land. Dieser Erfolg spiegelt das wachsende Marktsegment der Tiergesundheit in den USA wider, das bis 2030 voraussichtlich 11,3 Milliarden Dollar erreichen wird.
- Appointment of experienced sales manager Cindy Gill to expand market presence
- Spryng used by over 800 veterinary clinics across 50 states
- Distribution of more than 10,000 Spryng syringes nationwide
- Growing adoption of Spryng in the fast-expanding U.S. animal health market
- None.
MINNEAPOLIS, MN, Oct. 21, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading provider of biomedical therapeutics for equines and companion animals, has appointed Cindy Gill to the position of field veterinary business development manager for the entire states of Oklahoma and Arkansas and the northern region of Texas.
“Cindy’s experience and strong record of sales achievement with veterinary clinics brings to our sales team a valuable resource for achieving our business goals,” PetVivo CEO, John Lai. “Her experience with other veterinary products and her knowledge of clinic operations enables her to prioritize and better address the veterinarians and clinics in our sales pipeline.”
Gill brings to PetVivo significant knowledge and a strong background in the veterinary industry. She previously served as an outside sales representative for Lintbells, Ltd., the maker of YuMove®. Cindy also excelled as an inside sales representative for companies, such as Midwest Veterinary Supply and Merck. She also has a tremendous clinical background achieved by working as a veterinary technician for Town and Country Veterinary Hospital. Cindy earned her Bachelor of Science degree in Animal Science, Agriculture, Agriculture Operations and Related Sciences from West Texas A&M University in Canyon, Texas, as well as received a Master of Business Administration in Animal Science from West Texas A&M University.
Gill will focus on expanding sales of PetVivo’s flagship product, Spryng™ with OsteoCushion™ Technology, a revolutionary veterinary medical device that is transforming joint health for animals nationwide.
The unique injectable medical device has garnered widespread attention for its effectiveness in the management of osteoarthritis and other musculoskeletal conditions.
In multiple independent clinical studies, Spryng has been shown to improve the medical outcomes of animals suffering from lameness and other joint related afflictions.
By mimicking and reinforcing natural joint cartilage, Spryng represents a highly effective, drug-free option for veterinarians looking for long-term solutions that can improve the mobility and quality of life for equines and companion animals.
“It is amazing how the use of Spryng has contributed to how veterinarians approach joint health,” said Gill. “I am incredibly excited to join the PetVivo sales team with members in their efforts towards the development and commercialization of such life-changing medical devices.”
PetVivo recently achieved key major milestones with Spryng, with it having been used by more than 800 veterinary clinics across 50 states. This widespread, growing adoption has resulted in the distribution milestone of more than 10,000 Spryng syringes nationwide.
The increasing success of Spryng is reflective of the fast-growing U.S. animal health market, which is projected to double to
For more information about Spryng, please contact info1@petvivo.com or visit petvivo.com and sprynghealth.com.
To learn more about PetVivo as a publicly traded company, contact John Lai of PetVivo at (952) 405-6216 or Ron Both of CMA at (949) 432-7557 or submit your request here.
About PetVivo Holdings
PetVivo Holdings, Inc. (OTCQB: PETV, PETVW) is a biomedical device company focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The company is pursuing a strategy of developing and commercializing human therapies for the treatment of companion animals in capital and time efficient ways. A key component of this strategy is an accelerated timeline to revenues for veterinary medical devices that can enter the market much earlier than more stringently regulated human pharmaceuticals and biologics.
PetVivo has developed a robust pipeline of products for the medical treatment of animals and people, with a portfolio of 21 patents that protect the company's biomaterials, products, production processes and methods of use. The company’s commercially launched flagship product, Spryng™ with OsteoCushion™ Technology, is a veterinarian-administered, intra-articular injectable designed for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses.
For more information about PetVivo and its revolutionary Spryng with OsteoCushion Technology, email info1@petvivo.com or visit petvivo.com or sprynghealth.com.
Disclosure Information
PetVivo uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the company’s Investor Relations website, in addition to following the company’s press releases, SEC filings, public conference calls, presentations and webcasts.
Forward-Looking commercial Statements
The foregoing information regarding PetVivo Holdings, Inc. (the “Company”) may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2024 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
YuMove® is a registered trademark of Lintbells, Ltd.
Company Contact
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216
FAQ
What is PetVivo's stock symbol?
Who did PetVivo appoint as the new regional business development manager?
What is PetVivo's flagship product?
How many veterinary clinics have used Spryng?
What is the projected value of the U.S. animal health market by 2030?
